<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00737100</url>
  </required_header>
  <id_info>
    <org_study_id>205.339</org_study_id>
    <secondary_id>2008-001156-43</secondary_id>
    <nct_id>NCT00737100</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Parallel Group Study to Investigate the Safety and Efficacy of Two Doses of Tiotropium Bromide (2.5 mcg and 5 mcg) Administered Once Daily Via the Respimat Device for 12 Weeks in Patients With Cystic Fibrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This study evaluates the effects of 12-week treatment with two doses of tiotropium bromide
      (2.5 mcg q.d. and 5 mcg q.d.) compared to placebo administered via the Respimat device on
      lung function in patients with Cystic Fibrosis. The selection of the optimal dose will be
      based on bronchodilator efficacy, safety evaluations and pharmacokinetic evaluations
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Predicted FEV1 AUC0-4 Response at the End of Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Outcome measure description: Change from baseline in percent predicted Forced Expiratory Volume in one second (FEV1) Area Under the Curve from 0 to 4 hours (AUC0-4). Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Predicted FEV1 Trough Response at the End of Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Outcome measure description: Change from baseline in percent predicted trough Forced Expiratory Volume in one second. Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Predicted FVC AUC0-4 Response at the End of Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in percent predicted Forced Vital Capacity (FVC) Area Under the Curve from 0 to 4 hours (AUC0-4). Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Predicted FVC Trough Response at the End of Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in percent predicted trough Forced Vital Capacity (FVC). Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator FEF25-75 Percent Predicted at the End of Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Forced Expiratory Flow at 25-75% of vital capacity (FEF25-75). Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Residual Volume/Total Lung Capacity (RV/TLC) at the End of Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in static lung hyperinflation as measured by RV/TLC. Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory and Systemic Symptoms Questionnaire (RSSQ)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Outcome measure description: The RSSQ questionnaire is used to determine the presence or absence of an exacerbation during the recall period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CFQ Scores - Adult Group</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Cystic Fibrosis questionnaire (CFQ) is a disease-specific instrument that measures health-related quality of life (HRQOL) for adults with CF. This validation questionnaire consists of 50 items on generic and disease-specific scales. The scores range from 0 to 100, with higher scores indicating better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CFQ Scores - Adolescents Group</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Cystic Fibrosis questionnaire (CFQ) is a disease-specific instrument that measures health-related quality of life (HRQOL) for adolescents (age 6-13) with CF. This validation questionnaire consists of 50 items on generic and disease-specific scales. The scores range from 0 to 100, with higher scores indicating better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CFQ Scores - Parent Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Cystic Fibrosis questionnaire (CFQ) is a disease-specific instrument that measures health-related quality of life (HRQOL) for adolescents with CF - parent questionnaire. This validation questionnaire consists of 50 items on generic and disease-specific scales. The scores range from 0 to 100, with higher scores indicating better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Tiotropium Eliminated in Urine From 0 to 4 Hours at Steady State (Ae0-4,ss)</measure>
    <time_frame>pre-dose, and 5 minutes (min), 20 min, 1 hour (h), and 2 h post-dose</time_frame>
    <description>Ae0-4,ss represents the amount of tiotropium that is eliminated in urine from time 0 to 4 hours at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Measured Concentration at Steady State (Cmax,ss)</measure>
    <time_frame>pre-dose, and 5 minutes (min), 20 min, 1 hour (h), and 2 h post-dose</time_frame>
    <description>Cmax,ss represents the maximum measured concentration of tiotropium in plasma at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Dosing to the Maximum Concentration (Tmax,ss)</measure>
    <time_frame>pre-dose, and 5 minutes (min), 20 min, 1 hour (h), and 2 h post-dose</time_frame>
    <description>Tmax,ss represents the time from dosing to the maximum concentration of tiotropium in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Vital Signs and Laboratory Evaluation</measure>
    <time_frame>From first drug administration until 30 days after last drug administration (up to 121 days)</time_frame>
    <description>Clinical Relevant Abnormalities for Vital Signs and Laboratory evaluation. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Event.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">510</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Tiotropium Respimat 2.5 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive low dose tiotropium once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Respimat 5 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive high dose tiotropium once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Respimat</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient to receive placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Respimat</intervention_name>
    <description>patient to receive placebo matching active drug once daily</description>
    <arm_group_label>Placebo Respimat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium bromide 5 mcg</intervention_name>
    <description>patient to recieve high dose tiotropium once daily</description>
    <arm_group_label>Tiotropium Respimat 5 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium bromide-low dose-2.5mcg</intervention_name>
    <description>patient to receive low dose tiotropium once daily</description>
    <arm_group_label>Tiotropium Respimat 2.5 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female patients

          2. Diagnosis of Cystic Fibrosis (positive sweat chloride test or two identifiable
             mutations)

          3. Pre-bronchodilator FEV1 greater/equal 25% of predicted values

        Exclusion criteria:

          1. Significant history of allergy/hypersensitivity

          2. Hypersensitivity to study drug

          3. Participation in another trial

          4. Female patients who are pregnant or lactating

          5. Female patients of childbearing potential

          6. Patients who have started a new medication for CF within 4 weeks of screening

          7. Patients with known substance abuse

          8. Clinically significant disease other than CF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.339.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.100 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jette</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3310A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3317A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3317C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3317D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3317E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3314A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>BRON Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3314B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>BRON Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3314C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>BRON Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3302C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3302B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisieux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3304B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3308B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3308C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3301B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris Cedex 14</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3312A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3312C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3313A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3313B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3318A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3318C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3318G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3315C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roscoff Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3315D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roscoff Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3306B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3309A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.3316A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vannes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.49132 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.49133 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.49137 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.49134 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.49131 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gerlingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.49145 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.49135 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.49141 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.49140 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.49142 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.49130 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.233 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.231 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.234 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.171 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groesbeek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.170 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grafton / Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.221 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.225 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.223 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.224 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.07007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.07008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.44180 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.44190 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.44193 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.44192 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.44191 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.44185 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.44186 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.44183 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.44182 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.44194 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.44181 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.339.44184 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2008</study_first_submitted>
  <study_first_submitted_qc>August 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2008</study_first_posted>
  <results_first_submitted>March 21, 2011</results_first_submitted>
  <results_first_submitted_qc>March 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 13, 2011</results_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients randomised to receive matching placebo</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium Respimat 2.5 Micrograms</title>
          <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
        </group>
        <group group_id="P3">
          <title>Tiotropium Respimat 5 Micrograms</title>
          <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="159"/>
                <participants group_id="P3" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason discontinued not explained above</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients randomised to receive matching placebo</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium Respimat 2.5 Micrograms</title>
          <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
        </group>
        <group group_id="B3">
          <title>Tiotropium Respimat 5 Micrograms</title>
          <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="168"/>
            <count group_id="B2" value="166"/>
            <count group_id="B3" value="176"/>
            <count group_id="B4" value="510"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.4" spread="11.6"/>
                    <measurement group_id="B2" value="21.5" spread="12.0"/>
                    <measurement group_id="B3" value="20.7" spread="11.3"/>
                    <measurement group_id="B4" value="20.9" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 11 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian / Alaskan native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157.4" spread="17.2"/>
                    <measurement group_id="B2" value="157.7" spread="17.0"/>
                    <measurement group_id="B3" value="155.7" spread="18.2"/>
                    <measurement group_id="B4" value="156.9" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="19.0"/>
                    <measurement group_id="B2" value="51.0" spread="17.3"/>
                    <measurement group_id="B3" value="50.4" spread="18.2"/>
                    <measurement group_id="B4" value="51.2" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilogram/square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.3" spread="4.4"/>
                    <measurement group_id="B2" value="19.9" spread="4.0"/>
                    <measurement group_id="B3" value="20.0" spread="4.1"/>
                    <measurement group_id="B4" value="20.1" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol history</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Drinks no alcohol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks alcohol but should not interfere with trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks alcohol but could interfere with trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="167"/>
                    <measurement group_id="B4" value="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Predicted FEV1 AUC0-4 Response at the End of Week 12</title>
        <description>Outcome measure description: Change from baseline in percent predicted Forced Expiratory Volume in one second (FEV1) Area Under the Curve from 0 to 4 hours (AUC0-4). Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomised to receive matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Predicted FEV1 AUC0-4 Response at the End of Week 12</title>
          <description>Outcome measure description: Change from baseline in percent predicted Forced Expiratory Volume in one second (FEV1) Area Under the Curve from 0 to 4 hours (AUC0-4). Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
          <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.74" spread="0.65"/>
                    <measurement group_id="O2" value="1.20" spread="0.66"/>
                    <measurement group_id="O3" value="1.65" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 2.5 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Comment for p-value: Hierarchical testing was applied. Comparison of 2.5 dose to be performed only if superiority of tiotropium 5.0 dose compared to placebo was shown for both primary endpoints.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, center, visit and age group</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>4.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 5.0 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Comment for p-value: Hierarchical testing was applied. Comparison of 2.5 dose to be performed only if superiority of tiotropium 5.0 dose compared to placebo was shown for both primary endpoints.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, center, visit and age group</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.67</ci_lower_limit>
            <ci_upper_limit>5.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Predicted FEV1 Trough Response at the End of Week 12</title>
        <description>Outcome measure description: Change from baseline in percent predicted trough Forced Expiratory Volume in one second. Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomised to receive matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Predicted FEV1 Trough Response at the End of Week 12</title>
          <description>Outcome measure description: Change from baseline in percent predicted trough Forced Expiratory Volume in one second. Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
          <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="0.71"/>
                    <measurement group_id="O2" value="0.81" spread="0.71"/>
                    <measurement group_id="O3" value="0.78" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 2.5 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0184</p_value>
            <p_value_desc>Comment for p-value: Hierarchical testing was applied. Comparison of 2.5 dose to be performed only if superiority of tiotropium 5.0 dose compared to placebo was shown for both primary endpoints.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, center, visit and age group</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>4.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 5.0 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0179</p_value>
            <p_value_desc>Comment for p-value: Hierarchical testing was applied. Comparison of 2.5 dose to be performed only if superiority of tiotropium 5.0 dose compared to placebo was shown for both primary endpoints.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, center, visit and age group</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>4.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Predicted FVC AUC0-4 Response at the End of Week 12</title>
        <description>Change from baseline in percent predicted Forced Vital Capacity (FVC) Area Under the Curve from 0 to 4 hours (AUC0-4). Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomised to receive matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Predicted FVC AUC0-4 Response at the End of Week 12</title>
          <description>Change from baseline in percent predicted Forced Vital Capacity (FVC) Area Under the Curve from 0 to 4 hours (AUC0-4). Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
          <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="0.74"/>
                    <measurement group_id="O2" value="0.53" spread="0.74"/>
                    <measurement group_id="O3" value="1.81" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 2.5 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0756</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, center, visit and age group</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>3.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 5.0 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, center, visit and age group</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>5.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Predicted FVC Trough Response at the End of Week 12</title>
        <description>Change from baseline in percent predicted trough Forced Vital Capacity (FVC). Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomised to receive matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Predicted FVC Trough Response at the End of Week 12</title>
          <description>Change from baseline in percent predicted trough Forced Vital Capacity (FVC). Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
          <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.73"/>
                    <measurement group_id="O2" value="0.47" spread="0.72"/>
                    <measurement group_id="O3" value="0.81" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 2.5 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3857</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, center, visit and age group</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>2.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 5.0 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2199</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, center, visit and age group</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>3.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator FEF25-75 Percent Predicted at the End of Week 12</title>
        <description>Forced Expiratory Flow at 25-75% of vital capacity (FEF25-75). Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomised to receive matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator FEF25-75 Percent Predicted at the End of Week 12</title>
          <description>Forced Expiratory Flow at 25-75% of vital capacity (FEF25-75). Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
          <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="1.57"/>
                    <measurement group_id="O2" value="2.78" spread="1.55"/>
                    <measurement group_id="O3" value="3.94" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 2.5 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0363</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, center, visit and age group</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>8.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 5.0 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0073</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, center, visit and age group</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.45</ci_lower_limit>
            <ci_upper_limit>9.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Residual Volume/Total Lung Capacity (RV/TLC) at the End of Week 12</title>
        <description>Change from baseline in static lung hyperinflation as measured by RV/TLC. Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomised to receive matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Residual Volume/Total Lung Capacity (RV/TLC) at the End of Week 12</title>
          <description>Change from baseline in static lung hyperinflation as measured by RV/TLC. Calculated as percent predicted at week 12 minus percent predicted at baseline.</description>
          <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.03"/>
                    <measurement group_id="O2" value="0.00" spread="0.03"/>
                    <measurement group_id="O3" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 2.5 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7414</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, center, visit and age group</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 5.0 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1418</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline, center, visit and age group</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory and Systemic Symptoms Questionnaire (RSSQ)</title>
        <description>Outcome measure description: The RSSQ questionnaire is used to determine the presence or absence of an exacerbation during the recall period.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomised to receive matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory and Systemic Symptoms Questionnaire (RSSQ)</title>
          <description>Outcome measure description: The RSSQ questionnaire is used to determine the presence or absence of an exacerbation during the recall period.</description>
          <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one pulmonary exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pulmonary exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 2.5 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8515</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Covariates of treatment and age group</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Tiotropium 5.0 microgram dose versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5565</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Adjusted for baseline, center, visit and age group</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CFQ Scores - Adult Group</title>
        <description>The Cystic Fibrosis questionnaire (CFQ) is a disease-specific instrument that measures health-related quality of life (HRQOL) for adults with CF. This validation questionnaire consists of 50 items on generic and disease-specific scales. The scores range from 0 to 100, with higher scores indicating better health.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomised to receive matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CFQ Scores - Adult Group</title>
          <description>The Cystic Fibrosis questionnaire (CFQ) is a disease-specific instrument that measures health-related quality of life (HRQOL) for adults with CF. This validation questionnaire consists of 50 items on generic and disease-specific scales. The scores range from 0 to 100, with higher scores indicating better health.</description>
          <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical (N=99, 102, 105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="14.8"/>
                    <measurement group_id="O2" value="-0.0" spread="14.1"/>
                    <measurement group_id="O3" value="-2.9" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role (N=94, 100, 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="12.0"/>
                    <measurement group_id="O2" value="-2.7" spread="12.0"/>
                    <measurement group_id="O3" value="-2.1" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality (N=99, 101, 105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="15.0"/>
                    <measurement group_id="O2" value="-1.8" spread="16.4"/>
                    <measurement group_id="O3" value="-3.3" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotion (N=99, 101, 105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="11.5"/>
                    <measurement group_id="O2" value="-1.3" spread="13.5"/>
                    <measurement group_id="O3" value="0.1" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social (N=99, 101, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="12.3"/>
                    <measurement group_id="O2" value="-1.0" spread="10.7"/>
                    <measurement group_id="O3" value="-0.8" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body (N=99,101, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="18.4"/>
                    <measurement group_id="O2" value="-0.9" spread="15.3"/>
                    <measurement group_id="O3" value="1.7" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eat (N=99,101,106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="9.5"/>
                    <measurement group_id="O2" value="0.2" spread="10.3"/>
                    <measurement group_id="O3" value="0.0" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treat (N=99, 101, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="15.5"/>
                    <measurement group_id="O2" value="-1.4" spread="14.1"/>
                    <measurement group_id="O3" value="-1.7" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Health (N=99, 101, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="15.1"/>
                    <measurement group_id="O2" value="-3.2" spread="18.3"/>
                    <measurement group_id="O3" value="-0.6" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight (N=95, 101, 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="22.2"/>
                    <measurement group_id="O2" value="-3.3" spread="28.9"/>
                    <measurement group_id="O3" value="-0.0" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respirat (N=93, 101, 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="14.8"/>
                    <measurement group_id="O2" value="-3.7" spread="15.8"/>
                    <measurement group_id="O3" value="-1.8" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digest (N=93, 101, 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="14.9"/>
                    <measurement group_id="O2" value="-1.3" spread="13.7"/>
                    <measurement group_id="O3" value="0.3" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CFQ Scores - Adolescents Group</title>
        <description>The Cystic Fibrosis questionnaire (CFQ) is a disease-specific instrument that measures health-related quality of life (HRQOL) for adolescents (age 6-13) with CF. This validation questionnaire consists of 50 items on generic and disease-specific scales. The scores range from 0 to 100, with higher scores indicating better health.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomised to receive matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CFQ Scores - Adolescents Group</title>
          <description>The Cystic Fibrosis questionnaire (CFQ) is a disease-specific instrument that measures health-related quality of life (HRQOL) for adolescents (age 6-13) with CF. This validation questionnaire consists of 50 items on generic and disease-specific scales. The scores range from 0 to 100, with higher scores indicating better health.</description>
          <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical (N=46, 42, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="18.0"/>
                    <measurement group_id="O2" value="3.2" spread="14.8"/>
                    <measurement group_id="O3" value="-1.9" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>School (N=46, 42, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="14.3"/>
                    <measurement group_id="O2" value="-1.6" spread="10.9"/>
                    <measurement group_id="O3" value="-1.1" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body (N=46, 42, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="13.9"/>
                    <measurement group_id="O2" value="-0.3" spread="16.1"/>
                    <measurement group_id="O3" value="-0.1" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>School (N=46, 42, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="18.8"/>
                    <measurement group_id="O2" value="4.2" spread="19.2"/>
                    <measurement group_id="O3" value="2.4" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eat (N=46, 42, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="19.7"/>
                    <measurement group_id="O2" value="-2.4" spread="17.3"/>
                    <measurement group_id="O3" value="1.6" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treat (N=46, 42, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="16.5"/>
                    <measurement group_id="O2" value="-1.9" spread="20.1"/>
                    <measurement group_id="O3" value="5.7" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respirat (N=46, 42, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="15.2"/>
                    <measurement group_id="O2" value="1.2" spread="16.7"/>
                    <measurement group_id="O3" value="-3.0" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digest (N=46, 42, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="26.3"/>
                    <measurement group_id="O2" value="2.4" spread="26.9"/>
                    <measurement group_id="O3" value="-3.0" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CFQ Scores - Parent Questionnaire</title>
        <description>The Cystic Fibrosis questionnaire (CFQ) is a disease-specific instrument that measures health-related quality of life (HRQOL) for adolescents with CF - parent questionnaire. This validation questionnaire consists of 50 items on generic and disease-specific scales. The scores range from 0 to 100, with higher scores indicating better health.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomised to receive matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CFQ Scores - Parent Questionnaire</title>
          <description>The Cystic Fibrosis questionnaire (CFQ) is a disease-specific instrument that measures health-related quality of life (HRQOL) for adolescents with CF - parent questionnaire. This validation questionnaire consists of 50 items on generic and disease-specific scales. The scores range from 0 to 100, with higher scores indicating better health.</description>
          <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical (N=46, 45, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="15.4"/>
                    <measurement group_id="O2" value="4.9" spread="15.9"/>
                    <measurement group_id="O3" value="0.2" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotion (N=46, 45, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="11.2"/>
                    <measurement group_id="O2" value="0.0" spread="16.0"/>
                    <measurement group_id="O3" value="-0.1" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality (N=46, 44, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="12.3"/>
                    <measurement group_id="O2" value="3.3" spread="13.1"/>
                    <measurement group_id="O3" value="-1.5" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>School (N=46, 45, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="19.5"/>
                    <measurement group_id="O2" value="2.2" spread="26.3"/>
                    <measurement group_id="O3" value="0.4" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eat (N=46, 43, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="23.7"/>
                    <measurement group_id="O2" value="-0.8" spread="21.2"/>
                    <measurement group_id="O3" value="3.4" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body (N=46, 45, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="18.6"/>
                    <measurement group_id="O2" value="-1.7" spread="21.7"/>
                    <measurement group_id="O3" value="-3.2" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treat (N=46, 45, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="18.6"/>
                    <measurement group_id="O2" value="2.5" spread="16.4"/>
                    <measurement group_id="O3" value="-0.2" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Health (N=46, 45, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="21.4"/>
                    <measurement group_id="O2" value="3.5" spread="23.1"/>
                    <measurement group_id="O3" value="-3.0" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respirat (N=45, 43, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="16.4"/>
                    <measurement group_id="O2" value="-2.2" spread="18.8"/>
                    <measurement group_id="O3" value="-6.0" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digest (N=46, 43, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="15.6"/>
                    <measurement group_id="O2" value="-1.8" spread="17.0"/>
                    <measurement group_id="O3" value="1.1" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight (N=45, 45, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="35.5"/>
                    <measurement group_id="O2" value="1.5" spread="30.1"/>
                    <measurement group_id="O3" value="4.1" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Tiotropium Eliminated in Urine From 0 to 4 Hours at Steady State (Ae0-4,ss)</title>
        <description>Ae0-4,ss represents the amount of tiotropium that is eliminated in urine from time 0 to 4 hours at steady state</description>
        <time_frame>pre-dose, and 5 minutes (min), 20 min, 1 hour (h), and 2 h post-dose</time_frame>
        <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement - patients &gt;= 12 years</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Tiotropium Eliminated in Urine From 0 to 4 Hours at Steady State (Ae0-4,ss)</title>
          <description>Ae0-4,ss represents the amount of tiotropium that is eliminated in urine from time 0 to 4 hours at steady state</description>
          <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement - patients &gt;= 12 years</population>
          <units>ng</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" spread="73.0"/>
                    <measurement group_id="O2" value="245" spread="67.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Measured Concentration at Steady State (Cmax,ss)</title>
        <description>Cmax,ss represents the maximum measured concentration of tiotropium in plasma at steady state.</description>
        <time_frame>pre-dose, and 5 minutes (min), 20 min, 1 hour (h), and 2 h post-dose</time_frame>
        <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement - patients &gt;= 12 years</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration at Steady State (Cmax,ss)</title>
          <description>Cmax,ss represents the maximum measured concentration of tiotropium in plasma at steady state.</description>
          <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement - patients &gt;= 12 years</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.49" spread="58.5"/>
                    <measurement group_id="O2" value="9.95" spread="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Dosing to the Maximum Concentration (Tmax,ss)</title>
        <description>Tmax,ss represents the time from dosing to the maximum concentration of tiotropium in plasma</description>
        <time_frame>pre-dose, and 5 minutes (min), 20 min, 1 hour (h), and 2 h post-dose</time_frame>
        <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement - patients &gt;= 12 years</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Dosing to the Maximum Concentration (Tmax,ss)</title>
          <description>Tmax,ss represents the time from dosing to the maximum concentration of tiotropium in plasma</description>
          <population>Full Analysis Set (FAS) includes all participants having a baseline measurement and at least one post-dose measurement - patients &gt;= 12 years</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0830" lower_limit="0.0330" upper_limit="0.433"/>
                    <measurement group_id="O2" value="0.0830" lower_limit="0.0330" upper_limit="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Vital Signs and Laboratory Evaluation</title>
        <description>Clinical Relevant Abnormalities for Vital Signs and Laboratory evaluation. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Event.</description>
        <time_frame>From first drug administration until 30 days after last drug administration (up to 121 days)</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients randomised to receive matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Respimat 2.5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium Respimat 5 Micrograms</title>
            <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Vital Signs and Laboratory Evaluation</title>
          <description>Clinical Relevant Abnormalities for Vital Signs and Laboratory evaluation. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Event.</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood chloride decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood glucose increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood pressure increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood sodium decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophil count increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic enzyme increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oxygen saturation decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitamin K decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients randomised to receive matching placebo</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium Respimat 2.5 Micrograms</title>
          <description>Patients randomised to receive Tiotropium Respimat 2.5 micrograms once daily</description>
        </group>
        <group group_id="E3">
          <title>Tiotropium Respimat 5 Micrograms</title>
          <description>Patients randomised to receive Tiotropium Respimat 5.0 micrograms once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Aplastic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cystic fibrosis lung</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Distal intestinal obstruction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Overgrowth bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pleurisy viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Stenotrophomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipasaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Antibiotic prophylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="168"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="166"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

